<DOC>
	<DOCNO>NCT01994239</DOCNO>
	<brief_summary>The purpose study select best therapeutic strategy study effectiveness association short duration hormonal therapy radiotherapy compare radiotherapy alone , patient detectable PSA radical prostatectomy .</brief_summary>
	<brief_title>Comparison HT Concomitant With RT v RT Alone Patients With Detectable PSA After Prostatectomy</brief_title>
	<detailed_description>Study effectiveness association short duration hormonal therapy degarelix ( Firmagon ® ) radiotherapy , radiotherapy alone survival without event treatment detectable PSA radical prostatectomy . 122 patient include period 2 year . Patients treat accord follow scheme : - Arm A ( 61 patient ) : Pelvic Radiotherapy : 46 Gy prostate boost 66 Gy - Arm B ( 61 patient ) : Arm A + hormonal therapy degarelix 6 month</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Patient localize prostate adenocarcinoma treat radical prostatectomy ( whatever initial prognostic stage ) 2 . R0 R1 3. pN0 pNx 4 . Post prostatectomy PSA ≥ 0,2 ng/mL measure 1 month 4 month surgery increase second test perform 1 et 8 month post prostatectomy dosage 5 . PSA ≤ 2 ng/mL moment randomisation 6 . No clinical sign progressive disease ( bone scan PET scan abdominal pelvic scan MRI ) : N0 , M0 7 . Neutrophils ≥ 1500/mm3 ; platelet count ≥ 100 000/mm3 8 . Bilirubin ≤ ULN ; ALP , AST et ALT ≤ 1,5 ULN 9 . Creatinine &lt; 140 µmol/L ( clearance &gt; 60mL/min ) 10 . Normal fast glucose 11 . ECOG ≤ 1 12 . Age &gt; 18 year 13 . Life expectancy ≥ 10 year 14 . Patients invasive cancer complete response five year eligible 15 . Patients received information sheet sign informed consent form 16 . Patients public private health insurance coverage 1 . Prostate cancer histology adenocarcinoma 2 . Patients pN1 , N1 M1 3 . History pelvic radiotherapy 4 . Contraindication pelvic irradiation ( eg , scleroderma , chronic inflammatory bowel disease , etc. ) . 5 . Testosterone ≤ 0,5 ng/mL 6 . History surgical castration 7 . Previous treatment hormonotherapy 8 . Antineoplastic treatment progress 9 . History another invasive cancer within 5 year inclusion ( exception basal cell skin carcinoma treat ) 10 . Known pituitary adenoma 11 . Severe hypertension uncontrolled appropriate treatment ( 160 mm Hg systolic / 90 mm Hg diastolic ) 12 . Patient correct QT interval ( use Fridericia correction ) great 450 msec 13 . Individual deprive liberty place authority tutor 14 . Unable undergo medical monitoring test geographical , social psychological reason 15 . Known hypersensitivity treatment test 16 . Administration investigational therapeutic within 28 day prior screen visit treatment likely influence outcome</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Prostate-Specific Antigen</keyword>
	<keyword>LHRH antagonist</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>